Jon McGrath is a medtech entrepreneur and has led transformative therapeutic technology projects over the past 40 years.
Recently, Jon was a team lead in the RADx Tech program, the National Institutes of Health-funded accelerator that enabled daily test capacity of millions for SARS COV-2 in less than a year. Previously, Jon was CEO of Neograft Technologies (adaptive vascular grafts), and CEO at LumeRx (endoscopic phototherapy to treat H-pylori). Prior to that, he was Vice President of R&D at Biosphere Medical (vascular embolization, local drug delivery), Urologix (transurethral microwave ablation for enlarged prostate), Schneider/Pfizer (vascular stents, angioplasty systems), and Harbor Medical (vascular access systems). He began his career at Boston Scientific in various R&D and operations roles.
Jon is an advisor/trustee at Beth Israel Deaconess Hospital in Plymouth, and has a BS in Physics from the University of Vermont.